The PRIMA system, a testament to two decades of dedicated scientific pursuit, operates through an elegant synergy between a miniature camera integrated into a pair of advanced spectacles and a wireless chip surgically placed within the retina. The camera captures visual input and transmits it as infrared light to the implanted chip. This chip then ingeniously converts the infrared signals into electrical impulses, effectively bypassing the damaged photoreceptor cells responsible for detecting light and relaying visual information to the brain. These electrical signals then stimulate the remaining, intact retinal neurons, enabling the brain to interpret them as vision. The journey to this breakthrough was arduous, involving numerous prototypes, extensive animal testing, and an initial human trial, underscoring the persistence and innovation of the research team. Daniel Palanker, PhD, a professor of ophthalmology and co-senior author of the seminal paper published on October 20th in the prestigious New England Journal of Medicine, articulated the core concept that spurred this innovation: "I realized we should use the fact that the eye is transparent and deliver information by light." The device, once a distant vision conceived in 2005, has now demonstrated remarkable efficacy in patients.

The recent clinical trial focused on individuals suffering from the advanced stages of age-related macular degeneration, specifically geographic atrophy. This debilitating condition progressively erodes central vision and affects an estimated 5 million people globally, making it the leading cause of irreversible blindness in older adults. In macular degeneration, the delicate light-sensitive photoreceptor cells in the central retina deteriorate, leaving patients with only limited peripheral vision. Crucially, however, many of the retinal neurons responsible for processing visual information often remain functional. The PRIMA implant cleverly exploits these surviving neural pathways. The implant itself, a compact 2 by 2-millimeter device, is precisely positioned in the area of the retina where photoreceptor loss has occurred. Unlike natural photoreceptors that respond to visible light, the PRIMA chip is designed to detect infrared light emitted from the smart glasses. "The projection is done by infrared because we want to make sure it’s invisible to the remaining photoreceptors outside the implant," explained Palanker, highlighting a critical design element.

This ingenious design allows patients to seamlessly integrate their existing natural peripheral vision with the newly restored central vision provided by the implant. This dual vision capability significantly enhances their ability to navigate their environment and orient themselves. Palanker emphasized the importance of this simultaneous perception: "The fact that they see simultaneously prosthetic and peripheral vision is important because they can merge and use vision to its fullest." A further advantage of the PRIMA device lies in its photovoltaic nature. By relying solely on light to generate its electrical current, the implant operates wirelessly, eliminating the need for external power sources or invasive cables that could extend outside the eye, thus ensuring its safety and convenience.

The transformative impact of the PRIMA system was vividly demonstrated in the trial’s outcomes. The study enrolled 38 participants, all over the age of 60, who had geographic atrophy due to age-related macular degeneration and visual acuity worse than 20/320 in at least one eye. Following a four to five-week recovery period after the chip implantation in one eye, participants began using the smart glasses. While some individuals could discern patterns immediately, all participants experienced progressive improvements in their visual acuity over several months of dedicated training. Palanker likened this training period to that required for mastering prosthetic hearing with cochlear implants, noting, "It may take several months of training to reach top performance."

The results were nothing short of extraordinary. Of the 32 patients who completed the full year-long trial, an impressive 27 regained the ability to read. Furthermore, 26 participants demonstrated clinically meaningful improvement in their visual acuity, defined as the capacity to read at least two additional lines on a standard eye chart. On average, participants experienced a five-line improvement in their visual acuity, with one individual achieving an astonishing 12-line gain. The prosthesis proved invaluable in participants’ daily lives, enabling them to read books, decipher food labels, and recognize subway signs. The accompanying smart glasses offered advanced digital features, including adjustable contrast and brightness, and a magnification capability of up to 12 times, empowering users to customize their visual experience. User satisfaction was also high, with two-thirds of participants reporting medium to high levels of satisfaction with the device. While 19 participants experienced side effects such as ocular hypertension, peripheral retinal tears, and subretinal hemorrhage, none were life-threatening, and nearly all resolved within two months, underscoring the device’s overall safety profile.

Looking ahead, the PRIMA device, currently providing black-and-white vision, is poised for further enhancement. Palanker is actively developing software to introduce a full spectrum of grayscale, a crucial step for improving facial recognition, which he identified as a top priority for patients alongside reading. "Number one on the patients’ wish list is reading, but number two, very close behind, is face recognition. And face recognition requires grayscale," he stated. Concurrently, research is underway to engineer chips with higher resolution. The current resolution is limited by the 100-micron pixel size, with 378 pixels per chip. Future iterations, already tested in rats, aim for significantly smaller pixels, potentially as low as 20 microns, leading to an astonishing 10,000 pixels per chip. Palanker expressed optimism that this next generation of chips, when paired with sleeker glasses, could offer patients 20/80 vision, which, with electronic zoom, could approach 20/20 clarity. The research team is also exploring the application of this technology for other forms of blindness caused by photoreceptor loss. The collaborative spirit behind this monumental achievement is evident in the extensive list of contributing institutions from around the globe, including the University of Bonn, Germany; Hôpital Fondation A. de Rothschild, France; Moorfields Eye Hospital and University College London; and numerous other esteemed medical and academic centers. Funding for this pivotal study was provided by Science Corp., the National Institute for Health and Care Research, Moorfields Eye Hospital National Health Service Foundation Trust, and University College London Institute of Ophthalmology, further solidifying the collaborative and well-supported nature of this breakthrough.